Brokerage Firm Rating Update on Abbott Laboratories (ABT)

Abbott Laboratories (ABT) : The consensus on Abbott Laboratories (ABT) based on 15 analyst recommendation on the company stock is 1.6, which is interpreted as a Buy recommendation. Zacks Investment Research has issued a rank of 3 which endorses a Hold on the stock. However, 10 brokers have a differing view as they consider the stock to be a Strong Buy at current levels. 1 analyst believes that the stock is a Buy, which can produce decent returns in the future. 4 experts consider that the stocks earnings and the quoted price is in harmony, hence, they give it a Hold rating.

Abbott Laboratories (ABT) has been rated by 11 research analysts. Fundamentally, the highest shorterm price forecast for the stock is expected to reach $52 and the lowest price target forecast is $45. The average forecast of all the analysts is $48.82 and the expected standard deviation is $1.78.


For the current week, the company shares have a recommendation consensus of Buy. Also, Brokerage firm Jefferies maintains its rating on Abbott Laboratories (NYSE:ABT). As per the latest information, the brokerage house raises the price target to $52 per share from a prior target of $49. The shares have been rated Buy. The rating by the firm was issued on August 4, 2016.

Abbott Laboratories (NYSE:ABT): stock was range-bound between the intraday low of $41.77 and the intraday high of $42.29 after having opened at $42.15 on Wednesdays session. The stock finally closed in the red at $42.15, a loss of -0.62%. The stock remained in the red for the whole trading day. The total traded volume was 11,063,629 shares. The stock failed to cross $42.29 in Wednesdays trading. The stocks closing price on Thursday was $42.16.

Abbott Laboratories (Abbott) is engaged in the discovery, development, manufacture and sale of a range of health care products. Abbott operates in four business segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Vascular Products. The Established Pharmaceutical Products segment includes the international sales of a line of branded generic pharmaceutical products. The Diagnostic Products segment includes the sales of a line of adult and pediatric nutritional products. The Nutritional Products includes the sales of diagnostic systems and tests for blood banks, hospitals, commercial laboratories and alternate-care testing sites. The Vascular Products includes the sales of coronary, endovascular, structural heart, vessel closure and other medical device products.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.